[Efficacy in medical cost of concurrent therapy for osteoporosis].
Medical cost of concurrent therapy (alphacalcidol and etidronate) for osteoporosis was compared with those of no treatment and single therapies (alphacalcidol or etidronate) . Although concurrent therapy reduced by one fifth in medical costs for low back pain and fractures, 3 to 6 times reduced medical costs were consumed in those for pharmaceutical therapies, radiological examinations and so on by concurrent therapy compared with no treatment and single therapies.